Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Remitogen

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apolizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Novel antigenic targets for immunotherapy in myeloma
Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy after non-Hodgkin lymphoma and remains… Expand
Is this relevant?
Review
2003
Review
2003
Commentary (O'Brien): Current Status of Monoclonal Antibody Therapy for Chronic Lymphocytic Leukemia
Dr. Nabhan and his coauthors have written a comprehensive review of the use of monoclonal antibodies in the treatment of chronic… Expand
Is this relevant?
2002
2002
In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells
The humanized monoclonal antibody Hu1D10 (Remitogen™3;, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of… Expand
Is this relevant?
2002
2002
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
Antibody-based approaches have become a novel treatment modality for lymphoma patients. Humanized 1D10 (Hu1D10; Remitogen) is… Expand
Is this relevant?
2002
2002
Protein design labs begins Phase I trial of Remitogen in cancer patients with solid tumors.
  • Expert review of anticancer therapy
  • 2002
    • Corpus ID: 34566663
 
Is this relevant?
2001
2001
Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE